MedTrace Logo

Angiotensin Metabolite Profile After Subarachnoid Hemorrhage

NCT05222542 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2022-03-02

No results posted yet for this study

Summary

The outcome of subarchnoid hemorrhage depends on the severity of the bleeding and the development of secondary neurologic deficits caused by cerebral vasospasm. The primary endpoint is a comparison of renin angiotensin system (RAS) parameters (plasma concentrations of Angiotensin \[Ang\] I, Ang II, Ang 1-7, and Ang 1-5, angiotensin metabolite based markers of RAS enzyme activities as well as active ACE and ACE2 concentrations in plasma and CSF) between patients with and without vasospasm, mechanical ventilation, antihypertensive therapy with a RAS modifying drug and low versus high Hunt and Hess grade of subarachnoid hemorrhage.

Conditions

  • Subarachnoid Hemorrhage, Aneurysmal

Interventions

OTHER

Sampling of plasma and cerebrospinal fluid at specified time points

Samples (plasma, and in patients with in-dwelling cerebrospinal fluid drainages also cerebrospinal fluid) will be taken within 72 hours of subarachnoid hemorrhage and 7, 14 and 21 days following initial bleeding. Another plasma sample will be obtained if an antihypertensive therapy with a RAS modifying drug has been started.

Sponsors & Collaborators

  • Austrian Science Fund (FWF)

    collaborator OTHER

  • Dr. Roman Ullrich

    lead OTHER

Principal Investigators

  • Katharina Krenn, MD, PhD · Medical University of Vienna

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-01
Primary Completion
2025-02-28
Completion
2025-02-28

Countries

  • Austria

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05222542 on ClinicalTrials.gov